000 01292 a2200397 4500
005 20250515010040.0
264 0 _c20060124
008 200601s 0 0 eng d
022 _a1214-6994
040 _aNLM
_beng
_cNLM
100 1 _aKalousová, M
245 0 0 _aAdvanced glycoxidation end products in patients with multiple sclerosis.
_h[electronic resource]
260 _bPrague medical report
_c2005
300 _a167-74 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aArginine
_xanalogs & derivatives
650 0 4 _aCerebrospinal Fluid Proteins
_xanalysis
650 0 4 _aFemale
650 0 4 _aGlycation End Products, Advanced
_xmetabolism
650 0 4 _aHumans
650 0 4 _aLysine
_xanalogs & derivatives
650 0 4 _aMale
650 0 4 _aMultiple Sclerosis
_xmetabolism
650 0 4 _aMyelin Basic Protein
_xmetabolism
650 0 4 _aReceptor for Advanced Glycation End Products
650 0 4 _aReceptors, Immunologic
_xmetabolism
700 1 _aHavrdová, E
700 1 _aMrázová, K
700 1 _aSpacek, P
700 1 _aBraun, M
700 1 _aUhrová, J
700 1 _aGermanová, A
700 1 _aZima, T
773 0 _tPrague medical report
_gvol. 106
_gno. 2
_gp. 167-74
999 _c15938434
_d15938434